GSK features a robust and rapidly expanding oncology portfolio anchored by established therapies and innovative pipeline candidates targeting various solid tumors and hematologic malignancies. Key products include Jemperli (dostarlimab), an anti-PD-1 immunotherapy approved for endometrial and other mismatch repair-deficient cancers; Zejula (niraparib), a PARP inhibitor utilized in ovarian cancer maintenance; and Blenrep (belantamab mafodotin) for multiple myeloma. Additionally, the portfolio incorporates newly acquired next-generation precision kinase inhibitors and antibody-drug conjugates directed at lung cancer and other difficult-to-treat solid tumors.